17
edits
Changes
mLine 114:
Line 114: − <blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 2, 3, 4]</blockquote> − Typical FL has CD10+, BL2+. Atypical FL subgroups CD10- and/or BCL2 - all FL are STMN+ - useful differentiator between atypical FL and MZL [9]+ Line 134:
Line 133: − <blockquote class="blockedit">{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}[1, 9, 10]</blockquote> − Put your text here and fill in the table+ Line 147:
Line 145: − + − EXAMPLE 30% (add reference) − |Yes − + − + − + − The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).
→Clinical Features
==Immunophenotype==
==Immunophenotype==
Typically, FL is CD10+, BL2+. Atypical FL subgroups CD10- and/or BCL2 - all FL are STMN+ - useful differentiator between atypical FL and MZL [9]
{| class="wikitable sortable"
{| class="wikitable sortable"
==Chromosomal Rearrangements (Gene Fusions)==
==Chromosomal Rearrangements (Gene Fusions)==
<br />
{| class="wikitable sortable"
{| class="wikitable sortable"
!Notes
!Notes
|-
|-
|EXAMPLE t(9;22)(q34;q11.2)||EXAMPLE 3'ABL1 / 5'BCR||EXAMPLE der(22)||EXAMPLE 20% (COSMIC)
|t(14;18)(q32;q21)||5' IGH / 3' BCL2||der(18)||80%~90%
|No
|No
|Yes
|No
|EXAMPLE
|No
|Rarely, BCL2 rearrangement may also be observed with IGK at 2p11.2 or IGL at 22q11.22.
|}
|}